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Bone remodeling occurs at the bone surface throughout adult life and associates
bony quantity and quality. This process is a balance between the osteoblastic bone
formation and osteoclastic bone resorption, which cross-talks together. Semaphorin
3A is a membrane-associated secreted protein and regarded as a diffusible axonal
chemorepellent, which has been identified in the involvement of bone resorption and
formation synchronously. However, the role of Semaphorin 3A in bone homeostasis and
diseases remains elusive, in particular the association to osteoblasts and osteoclasts.
In this review article, we summarize recent progress of Semaphorin 3A in the bone
mass, homeostasis, and diseases and discuss the novel application of nerve-based
bone regeneration. This will facilitate the understanding of Semaphorin 3A in skeletal
biology and shed new light on the modulation and potential treatment in the bone
disorders.
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INTRODUCTION
Semaphorin 3A (Sema3A), also known as C-Collapsin-1, H-Sema III, M-SemD, R-Sema III,
Sema-Z1a, is a membrane-associated secreted protein (Behar et al., 1996; Ieda et al., 2007; Fukuda
et al., 2013). It was originally identified as a diffusible axonal chemorepellent that modulates
axon guidance and growth. Sema3A belongs to the semaphorin family and is firstly identified
in the involvement of patterning neuronal connections. This includes neuronal migration and
axon guidance in the development of the nervous system (Zanata et al., 2002; Kruger et al., 2005).
Semaphorin protein was firstly found in brain that induces the collapse and stalling of neuronal
growth cones, which was named collapsin (Luo et al., 1993). Up to date, semaphorin family has
been regarded as one of the key chemorepellents or chemoattractants that is involved in axon
steering, fasciculation, branching and synapse formation (Goodman et al., 1999). In particular,
Sema3A is not only a chemorepellent for cortical axons but also a chemoattractant for cortical apical
dendrites (Polleux et al., 2000). Although Sema3A was initially identified in the neuronal guidance,
it has further been reported in the association of bone biology, cardiac development, cancer
progression and immune disorders (Behar et al., 1996; Moretti et al., 2008; Carrer et al., 2012).
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These findings suggest that Sema3A is involved in the
organogenesis, vascularization and angiogenesis (Behar et al.,
1996; Neufeld and Kessler, 2008; McKenna et al., 2014).
Central and peripheral nerve systems play important roles in
the regulation of bone which is a densely innervated structure
(Calvo and Forteza-Vila, 1969; Serre et al., 1999). This process
includes many factors such as leptin, neuropeptide Y (NPY),
cocaine and amphetamine regulated transcript (CART) and
neuromedin U (NMU; Takeda, 2008). Sema3A has been reported
to repel trigeminal and dorsal root ganglia which are involved in
bone innervation (Kitsukawa et al., 1997; Taniguchi et al., 1997).
Recent studies have suggested that Sema3A can suppress bone
resorption and enhance bone formation synchronously (Hayashi
et al., 2012; Negishi-Koga and Takayanagi, 2012). However, the
role of Sema3A in the osteogenesis and osteclastgenesis still
remains elusive.
In this review article, we will discuss the recent progresses
of Sema3A in the bone mass, homeostasis and diseases and
highlight the novel findings of Sema3A in the regulation
of osteoblasts and osteoclasts. Additionally, this will facilitate
the understanding of its role in skeletal biology and shed
new light on the modulation and treatment in the bone
disorders.
SEMAPHORIN 3A AND ITS RECEPTORS
The semaphorin family has a conserved 500 amino-terminal
seven-bladed β-propeller semaphorin domain. A short
cysteine-rich plexin-semaphorins-integrin (PSI domain) is
in the N-terminal and additional sequence motifs are in the
class-specific C terminus (Goodman et al., 1999; Janssen et al.,
2010; Nogi et al., 2010). The semaphorin family includes
eight subclasses (Figure 1). The class 1 and 2 are present in
the invertebrate, whereas class 3–7 are present in vertebrates
(Goodman et al., 1999). The class V is encoded by viruses. These
classes differ in membrane anchorage that includes secreted,
transmembrane (TM), and glycosylphosphatidylinositol (GPI)-
linked types (Goodman et al., 1999). TM domain exists in
class 1, 4, 5 and 6 while GPI linkage only exists in class 7
(Goodman et al., 1999). Immunoglobulin (Ig) domain is present
in all classes except class 1, 5 and 6. The class 3, one of the
only secreted forms of semaphorin in vertebrates, contains
semaphorin domain, Ig domain and short basic domain
(Goodman et al., 1999).
Plexins and neuropilins family are two major receptors for
semaphorins (Figure 2). Plexins are one of the large type 1 single-
transmembrane-spanning cell surface receptors which comprise
at least nine members in four subclasses, plexin A, B, C and D
(Janssen et al., 2010). Plexins show high structural homology
and share the same signature feature with semaphorins. This
is an N-terminal semaphorin domain followed by a short
PSI domain. Furthermore, plexins contain two additional PSI
domains plus six Ig domains shared by plexins and transcription
factors (IPT; Janssen et al., 2010; Nogi et al., 2010). Plexins
have been involved in the binding of semaphorins that play
a role in the signal transduction. For example, Plexin B1 is a
receptor for semaphorin 4D and plexin C1 is a receptor for
semaphorin 7A, and plexin As (PlexinA1, A2, A3 and A4)
are receptors for the class 3 and 6 semaphorins (Kolodkin
et al., 1997; Takahashi et al., 1999; Tamagnone et al., 1999;
Tran et al., 2007). Plexin A can directly bind semaphorin
6 through contacts of the conserved part of the semaphorin
domains (Janssen et al., 2010). However, plexin A binds class
3 semaphorins in an indirect way, as plexin A conjugates one
of two neuropilins (Neuropilin 1 or Neuropilin 2) to generate
holoreceptors for these semaphorins (Kolodkin et al., 1997;
Takahashi et al., 1999; Tamagnone et al., 1999; Tran et al., 2007).
Additionally, neuropilin 1 (Nrp1) and neuropilin 2 (Nrp2) bind
to Sema3A with different affinities (He and Tessier-Lavigne,
1997; Kolodkin et al., 1997). One of the major determinants
for the affinity is the C terminus of semaphorins (Giger et al.,
1998; Lee et al., 2003). For example, semaphorin 3F binds to
Nrp2 with high affinity and to Nrp1 with much lower affinity.
Conversely, Sema3A binds to Nrp1 with high affinity and this is
an exclusive signaling pathway (He and Tessier-Lavigne, 1997;
Kolodkin et al., 1997).
The neuropilins are single-transmembrane-spanning
cell-surface glycoproteins that have a large extracellular domain,
a single transmembrane domain, and a short cytoplasmic tail.
The extracellular domain comprises two N-terminal CUB motifs
(domain a1 and a2), two coagulation factor V/VIII homology
domains (domain b1 and b2) and a membrane-proximal MAM
domain (domain c; Soker et al., 1998; Antipenko et al., 2003;
Janssen et al., 2012). Both domain a and b are essential in
the binding of the Sema3A. Domain b1 is involved in the
interaction with vascular endothelial growth factor (VEGF)
and the basic carboxy terminus of Sema3A. Domain c has been
reported to mediate neuropilins dimerization that interacted
with other membrane receptors. Domain c indirectly interacts
with either semaphorin or VEGF ligands. For example, Sema3A
need co-receptors formed by neuropilins and plexin As (Chen
et al., 1998; Giger et al., 1998; Nakamura et al., 1998; Lee et al.,
2003).
SEMA3A EMERGES IN SKELETAL SYSTEM
Bone tissue is renewed throughout adult life and this process
is called bone remodeling (Negishi-Koga and Takayanagi,
2012). It mainly occurs at the bone surface and includes the
osteoblastic bone formation and osteoclastic bone resorption.
This remodeling is a balance not only for normal bone mass
and strength, but also for mineral homeostasis. If the balance
has been disrupted between the bone formation and resorption,
it causes bone disorders including osteoporosis, osteopetrosis,
osteonecrosis (Teitelbaum, 2000; Grayson et al., 2015). Bone
remodeling not only relies on bone cells including osteoblasts,
osteoclasts and osteocytes, but also is linked tightly through
coupling factors, including growth factors released from the
matrix, soluble and membrane products of osteoclasts and their
precursors, signals from osteocytes and from immune cells and
signaling taking place within the osteoblast lineage (Negishi-
Koga and Takayanagi, 2012).
Numerous factors have been identified in the participation
of bone remodeling. Receptor activator of nuclear factor
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κB (RANK), receptor activator of nuclear factor κB ligand
(RANKL), macrophage colony-stimulating factor (M-CSF),
Osteoprotegerin (OPG), interleukin (IL) and many other factors
have been demonstrated to associate with bone resorption.
Transforming growth factor β (TGF-β), bone morphogenetic
proteins (BMPs), Wnt signaling have been shown to be involved
in bone formation (Sims and Martin, 2014). Most of these
factors participate in the regulation of one aspect, either
bone formation or resorption. For example, OPG protects
bone by inhibiting osteoclastic bone resorption rather than
the stimulation of osteoblastic bone formation (Togari et al.,
2000).
Up to date, studies have suggested that Sema3A is in the
regulation of bone resorption and formation synchronously. It
suppressed bone resorption and increased bone formation to
exert an osteoprotective effect (Hayashi et al., 2012; Negishi-
Koga and Takayanagi, 2012). Behar et al. (1996) have generated
Sema3a deficient mice by homologous recombination. Although
the homozygous progeny were similar to their littermates at
birth, most of them died over the following 3 months, only
12% were viable to adulthood. The surviving homozygous
mice not only showed a paucity of neuropil, abnormal neuron
orientation in the cerebral cortex, inappropriate sensory axons
projection into the spinal cord, but also showed hypertrophy
of the right ventricle, dilation of the right atrium and certain
embryonic bones and abnormal development in cartilage
(Behar et al., 1996). Knockout of the Sema3A gene also
induced abnormal bone and cartilage development of the
rat (Gomez et al., 2005). Additionally, Sema3A has been
reported to precede or coincide with the invasion of bone
by blood vessels and nerve fibers, not only in the temporal
but also at the spatial level. Sema3A and its receptors
were identified in the prehypertrophic and hypertrophic
chondrocytes in ossification centers, around the periosteum,
with the onset of endochondral ossification and vascular
invasion (Gomez et al., 2005). Taken together, Sema3A is
expressed in bone and involved in the regulation of innervation
and blood vessel invasion, which may contribute to skeletal
patterning.
SEMA3A AFFECTS OSTEOBLASTS AND
OSTEOCLASTS
Sema3A signaling system is generally expressed in chondrocytes,
osteoblasts and osteoclasts (Behar et al., 1996). Sema3A is mainly
expressed by osteoblasts and its receptor Nrp1 is expressed by
osteoclast precursors. Osteoclastic-like multinucleated cells from
bone marrow have been demonstrated to express the ligands and
receptors of Sema3A already (Koshihara et al., 1999; Togari et al.,
2000).
Hayashi et al. (2012) observed a severe osteopenic phenotype
in Sema3a knock-out mice (Sema3a−/− mice), which was caused
by a decrease in the osteoblastic bone formation and an increase
in osteoclastic bone resorption. Fukuda et al. (2013) found
that Sema3a−/− mice showed a 25% decrease in the bone
mass due to a decrease in bone formation without an overt
change in the bone resorption at 3, 6 and 12 months of age,
although a non-significant increase was observed in a serum
bone resorption marker. In vitro, Sema3a−/− osteoblasts showed
a defect in cellular differentiation, with a decrease in alkaline
phosphatase (ALP) activity and osteoblast markers, although
the Sema3A treatment has rescued the defects in osteoblast
differentiation. By contrast, the Sema3A treatment caused a
decrease in osteoclast differentiation of osteoclast precursors,
which the multinucleated TRAP-positive osteoclasts and the
expression of osteoclast marker genes decreased (Fukuda et al.,
2013). As such, Sema3A is regarded to increase bone mass in
an autocrine fashion that stimulate osteoblast differentiation and
inhibit osteoclast differentiation.
For the pathway of Sema3A regulated-osteoblasts, Wnt
pathway has been identified already (Hayashi et al., 2012).
Sema3a−/− mice and Nrp1Sema− mice (mutant Nrp1 lacking
FIGURE 1 | The subunits of semaphorin family. The semaphorin family has been categorized into eight classes. The class 1 and 2 are present in the invertebrate,
whereas class 3–7 are present in vertebrates. The class V are encoded by viruses.
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FIGURE 2 | Holoeceptors for semaphorins. Plexin A has an N-terminal sema domain followed by three PSI domains plus six Ig domain shared by plexins and
transcription factors (IPT) domains in extracelluar. The intracellular domain comprises two split cytoplasmic GTPase-activating protein (GAP) domains and a GTPase
binding domain. The neuropilin1 has a large extracellular domain, a single transmembrane domain, and a short cytoplasmic tail. The extracellular domain comprises
two N-terminal CUB motifs (domain a1 and a2), two coagulation factor V/VIII homology domains (domain b1 and b2) and a membrane-proximal MAM domain
(domain c).
the Sema binding site) showed a decreased osteoblast number,
a reduced bone formation rate, and an increased adipocyte
number. Calvarial cells obtained from Sema3a−/− and
Nrp1Sema− mice were cultured in an osteogenic medium with
or without Sema3A. ALP activity and bone nodule formation
were markedly decreased and the adipogenic differentiation was
highly increased in both Sema3a−/− and Nrp1Sema−cells. This
has been rescued by the treatment of Sema3A in Sema3a−/− cells
rather than inNrp1Sema−cells. In Sema3a−/− cells, the expression
of Runx2, Sp7, Alpl and Bglap genes, associated with osteoblasts,
were strongly suppressed, and the expression of Pparg, Cebpa,
Fabp4 and Lpl, associated with adipocytes, was highly increased.
It is believed that Sema3A activated osteoblast differentiation
and inhibited adipocyte differentiation through Nrp1 (Hayashi
et al., 2012). The canonical Wnt/β-catenin signaling pathway
played an important role in the promotion of the osteogenic
differentiation of MSCs. β-catenin has been identified to induce
osteogenic differentiation and inhibit adipogenic differentiation
(Case and Rubin, 2010; Cawthorn et al., 2012). Both the mRNA
expression of most of the transcriptional targets of β-catenin
and the Wnt3a-induced nuclear accumulation of β-catenin
were suppressed in Sema3a−/− calvarial cells (Hayashi et al.,
2012). Rac1 activation can promote nuclear accumulation
of β-catenin in response to Wnt signaling (Wu et al., 2008).
Notably, in Sema3a−/− calvarial cells, the activation of Rac
in response to Wnt3a treatment was significantly decreased.
Sema3A facilitated the nuclear translocation of β-catenin and
the activation of Rac (Hayashi et al., 2012). Sema3A stimulates
Rac1 activation through FARP2, which is a Dbl-family guanine
nucleotide exchange factor (GEF) involved in the response
of neuronal growth cones (Toyofuku et al., 2005; He et al.,
2013). As such, it is regarded that Sema3A activates the
canonical Wnt/β-catenin pathway in the process of osteoblast
differentiation. FARP2-mediated activation of Rac1 was involved
in this response (Hayashi et al., 2012; Figure 3).
Sema3A has been reported in the suppression of osteoclast
differentiation. Osteoblasts express two cytokines, M-CSF
and receptor activator of nuclear factor-κB ligand (RANKL),
which are essential for the osteoclast differentiation (Boyle
et al., 2003; Yamashita et al., 2012). Bone marrow-derived
monocyte/macrophage precursor cells (BMMs) are osteoclast
FIGURE 3 | Sema3A signaling in bone remodeling. Sema3A increases
bone mass by the stimulation of osteoblast differentiation and inhibition of
osteoclast differentiation. Same3A regulates osteoblasts through
Wnt/β-catenin pathway. Sema3A inhibits osteoclast differentiation through the
arresting of PLCγ activation and calcium oscillation. Additionally, the inhibition
of RhoA suppresses the migration of osteoclast precursors that are bone
marrow-derived monocyte/macrophage precursor cells (BMMs).
Frontiers in Cellular Neuroscience | www.frontiersin.org 4 February 2017 | Volume 11 | Article 40
Li et al. Semaphorin 3A Works in Skeleton
precursors. BMMs expressed c-Fms (M-CSF receptor) and
RANK (RANKL receptor) and differentiated into osteoclasts in
the presence of M-CSF and RANKL (Yamashita et al., 2012).
OPG produced by osteoblasts was a soluble decoy receptor
for RANKL and inhibited osteoclastogenesis by blocking the
RANKL-RANK interaction (Simonet et al., 1997; Boyle et al.,
2003).
Sema3A inhibited M-CSF-induced osteoclast differentiation
through Rho A signaling pathway (Hayashi et al., 2012).
A repulsive effect of Sema3A has been identified on the
M-CSF-induced migration of BMMs (Hayashi et al., 2012).
It is known that M-CSF induced the activation of the RhoA
and Rac GTPases. Sema3A treatment abrogated the activation
of RhoA activation in response to M-CSF, rather than the
Rac activation. Additionally, the inhibition of RhoA activation
caused the inhibitory effect of Sema3A on the migration of
BMMs (Hayashi et al., 2012). Sema3A inhibited RANKL-induced
tyrosine phosphorylation of phospholipase Cγ2 (PLCγ2) and
calcium oscillation through immune-receptor tyrosine-based
activation motif (ITAM) signaling pathway (Hayashi et al.,
2012). RANKL-induced osteoclastogenesis was dependent on a
co-stimulatory receptor signaling through ITAMs, including Fc
receptor common γ (FcRγ) and DNAX-activating protein of
12 kDa (DAP12; Koga et al., 2004). RANK and ITAM signaling
cooperated to induce NFATc1, which is the transcription of
osteoclast-specific genes. FcRγ and DAP12 were associated
with osteoclast-associated receptor (OSCAR) and triggering
receptor expressed on myeloid cells 2 (TREM2; Yamashita et al.,
2012).
PlexinA1 has been reported to interact with TREM2 and
DAP12 to form the receptor complex for Sema6D. This
ligand/receptor complex stimulated osteoclast differentiation
in osteoclast precursors by the ITAM signaling pathway
(Takegahara et al., 2006). Usually, Nrp1 as a receptor of Sema3A
forms a receptor complex with PlexinA1 in BMMs (Takahashi
and Strittmatter, 2001). With the increasing expression of
Nrp1, the amount of PlexinA1 binding to Nrp1 increased
and PlexinA1 binding to TREM2 decreased. With the down
regulation of Nrp1, RANKL induced the formation of the
PlexinA1-TREM2-DAP12 complex to release PlexinA1 from the
PlexinA1-Nrp1 complex. The Sema3A treatment inhibited
RANKL-induced formation of the PlexinA1-TREM2-
DAP12 complex by the suppression of Nrp1 and themaintenance
of the PlxnA1-Nrp1 complex (Hayashi et al., 2012). As such,
the Sema3A-Nrp1 axis inhibited the osteoclast differentiation,
which separated the PlexinA1 from the PlexinA1-TREM2-
DAP12 complex. This further suppressed the ITAM signaling
(Figure 3).
SEMA3A REGULATES BONE
REMODELING THROUGH SENSORY
NERVES
It has been generally regarded that bone remodeling is mainly
dependent on the local environment that includes autocrine and
paracrine mechanisms. With the new discovery of leptin in the
regulation of bone mass, both central and peripheral nervous
systems has been noted in the study of bone development
and homeostasis (Sandhu et al., 1987; Hill et al., 1991; Edoff
et al., 1997; Takeda et al., 2002; Elefteriou et al., 2014).
However, the molecular mechanisms by which neurons reach
their targets in bones are not very clear. Several families of
proteins involved in wiring and allow neurons to locate and
reach their targets, such as Semaphorins, Netrins, Slits and
Ephrins (Gomez et al., 2005). Togari et al has demonstrated
the constitutive expression of neorotrophins, Sema3A, netrin-1
and netrin-2-like protein in human osteoblastic and osteoclastic
cells. These axon guidance molecules are known to function
as a chemoattractant and/or chemorepellent for growing nerve
fibers (Togari et al., 2000). Particularly, it has been reported that
Sema3A signaling is very important for neuronal targeting in
the peripheral nervous system (Janssen et al., 2010; Nogi et al.,
2010).
It has been reported that Sema3A works as an autocrine
factor for neuronal development and neuron-derived Sema3A
contributes to normal nervous system development (Fukuda
et al., 2013). For instance, neuron-specific Sema3A deficient
mice, like Sema3a−/− mice, showed abnormal development in
the olfactory system and spinal cord, decreased thickness of the
cerebral cortex, and altered pattern of sympathetic innervation in
the heart (Behar et al., 1996; Ieda et al., 2007; Fukuda et al., 2013).
Neuron-specific Sema3A deficient mice were generated based on
synapsin-I-Cre mice (Sema3asynapisin−/−) and nestin-Cre mice
(Sema3anestin−/−; Zhu et al., 2001; Okada et al., 2006). Neuron-
specific Sema3A deficient mice, like Sema3a−/− mice, had a
phenotype of a low bone mass, which was due to the decreased
bone formation and increased bone resorption (Fukuda et al.,
2013). However, the osteoblast-specific Sema3A deficient mice
have been identified in normal bone formation and bone mass
(Rodda and McMahon, 2006). As such, neurons in the bones
were believed to take the responsibility for a substantial amount
of Sema3A expression and the decreased expression of Sema3a
in bone was only one of the causes of bone abnormality (Fukuda
et al., 2013).
Neurofilament-positive fibers, involved in peripheral
nerve innervations, were significantly decreased in both
Sema3a−/−mice and neuron-specific Sema3A deficient mice
(Fukuda et al., 2013). Additionally, sensory-positive nerves
markers such as CGRP and TRPV1 were decreased in bone
of Sema3a−/− mice and neuron-specific Sema3A deficient
mice. However, dopamine β-hydroxylase (DBH)-positive
sympathetic nerve fibers, inhibited bone mass accrual (Takeda
et al., 2002), were not significantly affected in these two
mice models (Fukuda et al., 2013). The decreased sensory
innervations are consistent with decreased bone mass in
neuron-specific Sema3A deficient mice. By contrast, in
osteoblast-specific Sema3A-deficient mice, which had normal
bone mass but decreased Sema3A expression in bone, the
projections of peripheral nerve fibers into bone tissues
were not affected. As such, the abnormal projections of
sensory fibers, not the expression of Sema3A in bone, are
responsible for the bone abnormalities in Sema3a−/− and
neuron-specific Sema3A deficient mice (Fukuda et al., 2013;
Figure 4).
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FIGURE 4 | Sema3A regulates bone remodeling through sensory innervation. Neuron-specific Sema3A deficient mice, like Sema3a−/− mice, have low bone
mass. Osteoblast-specific Sema3A deficient mice have normal bone formation and bone mass, although the expression of Sema3A decreases in bone. Additionally,
neurons in the bones are regarded to play a major role in the expression of Sema3A.
Fukuda et al. (2013) were the first to demonstrate that sensory
nerves play an important role in bone remodeling. Recently,
some interactions between sensory neurons and sprouting
sympathetic fibers have been observed (Xie et al., 2011). The
sympathetic nervous system is known to inhibit bone mass
accrual. Therefore, an interesting hypothesis is that there may
exist a balance between ‘‘osteo-anabolic’’ afferent sensory nerves
and ‘‘osteo-catabolic’’ efferent sympathetic nerves (Fukuda et al.,
2013).
Recent evidence suggests that both central and peripheral
nervous systems regulate bone remodeling (Karsenty and
Ferron, 2012). Based on a number of anatomic, pharmacologic
and genetic studies, the sympathetic nervous system
represents one of the main links between the central
nervous system and the skeleton (Elefteriou et al., 2014).
More evidence is needed to demonstrate whether Sema3A
regulates bone remodeling through the central nervous
system.
POTENTIAL TARGETS FOR BONE
DISEASES
To determine the therapeutic potential of Sema3A, Hayashi
et al injected wild-type mice with recombinant human Sema3A.
Intravenous administration in 5-week-old male mice led to
increased trabecular bone volume and trabecular parameters in
the distal femur. Bone morphometric analysis showed a decrease
in osteoclastic parameters and an increase in osteoblastic
parameters synchronously. Intravenous administration of
Sema3A also accelerated bone regeneration in a mice model
of bone cortical bone defects. As Sema3A treated mice showed
higher regenerated cortical bone volume and significantly
increased osteoblast surface and decreased osteoclast surface
around the injured region. Additionally, Sema3A administration
rescued bone loss in an ovariectomized mouse model of
postmenopausal osteoporosis. In vitro experiment is consistent
with in vivo as Sema3A suppressed osteoclastogenesis and
promoted osteoblastogenesis in cultured human cells (Hayashi
et al., 2012).
Local injection of Sema3A into the injury site in osteoporotic
rats increased callus volume and density at 4 weeks post-fracture,
and induced promoted callus ossification and remodeling
at 8 weeks post-fracture (Li et al., 2015). Furthermore,
rheumatoid arthritis synovial tissues showed decreased Sema3A
expression (Takagawa et al., 2013). Sema3A is overexpressed
in osteoarthritis cartilage and could play a role in chondrocyte
cloning through inhibition of cell migration in osteoarthritic
cartilage (Okubo et al., 2011). Sema3A is also proposed as a
marker for systemic lupus erythematosus (Vadasz et al., 2012).
Similarly, Sema3A may be a marker for bone disorders such as
osteoporosis. Sema3A not only repels neuronal ingrowth but also
may repel neovascularization within the healthy disc, this makes
Sema3A as a potential therapeutic target in the treatment of low
back pain (Tolofari et al., 2010).
In conclusion, Sema3A exerts an osteoprotective effect by
both suppressing bone resorption and increasing bone formation
at the same time. Sema3A can regulate bone remodeling either
via exerting effects on osteoblasts and osteoclasts, through
autocrine and paracrine mechanisms, or in the way of sensory
nerve innervation. This suggests that Sema3A take a part in
the skeletal biology. Accordingly, Sema3A is a promising new
therapeutic agent for bone diseases.
AUTHOR CONTRIBUTIONS
All authors designed, wrote, checked, revised and finalized the
manuscript.
FUNDING
This work is supported by grants from the National Natural
Science Foundation of China grant No. 81472078, 31470904,
Frontiers in Cellular Neuroscience | www.frontiersin.org 6 February 2017 | Volume 11 | Article 40
Li et al. Semaphorin 3A Works in Skeleton
31370992, 31670951 and Science and Technology Fund
of Sichuan Province No. 2013SZ0057, Shenzhen basic
research grant No. JCYJ20140417113430707, JSGG20160
429190521240, JCYJ20140417113430708, JSGG20160429
190521240; Shenzhen Peacock Plan KQCX20150331173
54153.
ACKNOWLEDGMENTS
We thank Prof. Fan Yang from MIT-Siat Brian Research Joint
Center, Dr. Shishu Huang from West China Hospital and
Dr. Zhihe Zhao fromWest China School of Stomatology for their
encouragement and guidance.
REFERENCES
Antipenko, A., Himanen, J. P., van Leyen, K., Nardi-Dei, V., Lesniak, J.,
Barton, W. A., et al. (2003). Structure of the semaphorin-3A receptor binding
module. Neuron 39, 589–598. doi: 10.1016/s0896-6273(03)00502-6
Behar, O., Golden, J. A., Mashimo, H., Schoen, F. J., and Fishman, M. C. (1996).
Semaphorin III is needed for normal patterning and growth of nerves, bones
and heart. Nature 383, 525–528. doi: 10.1038/383525a0
Boyle, W. J., Simonet, W. S., and Lacey, D. L. (2003). Osteoclast differentiation and
activation. Nature 423, 337–342. doi: 10.1038/nature01658
Calvo, W., and Forteza-Vila, J. (1969). On the development of bone marrow
innervation in new-born rats as studied with silver impregnation and electron
microscopy. Am. J. Anat. 126, 355–371. doi: 10.1002/aja.1001260308
Carrer, A., Moimas, S., Zacchigna, S., Pattarini, L., Zentilin, L., Ruozi, G., et al.
(2012). Neuropilin-1 identifies a subset of bone marrow Gr1- monocytes that
can induce tumor vessel normalization and inhibit tumor growth. Cancer Res.
72, 6371–6381. doi: 10.1158/0008-5472.can-12-0762
Case, N., and Rubin, J. (2010). β-catenin—a supporting role in the skeleton. J. Cell.
Biochem. 110, 545–553. doi: 10.1002/jcb.22574
Cawthorn, W. P., Bree, A. J., Yao, Y., Du, B., Hemati, N., Martinez-Santibañez, G.,
et al. (2012). Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate
osteoblastogenesis through a β-catenin-dependent mechanism. Bone 50,
477–489. doi: 10.1016/j.bone.2011.08.010
Chen, H., He, Z., Bagri, A., and Tessier-Lavigne, M. (1998). Semaphorin-
neuropilin interactions underlying sympathetic axon responses to class III
semaphorins. Neuron 21, 1283–1290. doi: 10.1016/s0896-6273(00)80648-0
Edoff, K., Hellman, J., Persliden, J., and Hildebrand, C. (1997). The developmental
skeletal growth in the rat foot is reduced after denervation. Anat. Embryol.
(Berl) 195, 531–538. doi: 10.1007/s004290050073
Elefteriou, F., Campbell, P., and Ma, Y. (2014). Control of bone remodeling by
the peripheral sympathetic nervous system. Calcif. Tissue Int. 94, 140–151.
doi: 10.1007/s00223-013-9752-4
Fukuda, T., Takeda, S., Xu, R., Ochi, H., Sunamura, S., Sato, T., et al. (2013).
Sema3A regulates bone-mass accrual through sensory innervations. Nature
497, 490–493. doi: 10.1038/nature12115
Giger, R. J., Urquhart, E. R., Gillespie, S. K., Levengood, D. V., Ginty, D. D.,
and Kolodkin, A. L. (1998). Neuropilin-2 is a receptor for semaphorin IV:
insight into the structural basis of receptor function and specificity. Neuron 21,
1079–1092. doi: 10.1016/s0896-6273(00)80625-x
Gomez, C., Burt-Pichat, B., Mallein-Gerin, F., Merle, B., Delmas, P. D.,
Skerry, T. M., et al. (2005). Expression of semaphorin-3A and its receptors
in endochondral ossification: potential role in skeletal development and
innervation. Dev. Dyn. 234, 393–403. doi: 10.1002/dvdy.20512
Goodman, C. S., Kolodkin, A. L., Luo, Y., Püschel, A. W., and Raper, J. A.
(1999). Unified nomenclature for the semaphorins/collapsins. Semaphorin
nomenclature committee. Cell 97, 551–552. doi: 10.1016/s0092-8674(00)
80766-7
Grayson, W. L., Bunnell, B. A., Martin, E., Frazier, T., Hung, B. P., and
Gimble, J. M. (2015). Stromal cells and stem cells in clinical bone regeneration.
Nat. Rev. Endocrinol. 11, 140–150. doi: 10.1038/nrendo.2014.234
Hayashi, M., Nakashima, T., Taniguchi, M., Kodama, T., Kumanogoh, A., and
Takayanagi, H. (2012). Osteoprotection by semaphorin 3A. Nature 485, 69–74.
doi: 10.1038/nature11000
He, X., Kuo, Y. C., Rosche, T. J., and Zhang, X. (2013). Structural basis for
autoinhibition of the guanine nucleotide exchange factor FARP2. Structure 21,
355–364. doi: 10.1016/j.str.2013.01.001
He, Z., and Tessier-Lavigne, M. (1997). Neuropilin is a receptor for the
axonal chemorepellent semaphorin III. Cell 90, 739–751. doi: 10.1016/s0092-
8674(00)80534-6
Hill, E. L., Turner, R., and Elde, R. (1991). Effects of neonatal sympathectomy
and capsaicin treatment on bone remodeling in rats. Neuroscience 44, 747–755.
doi: 10.1016/0306-4522(91)90094-5
Ieda, M., Kanazawa, H., Kimura, K., Hattori, F., Ieda, Y., Taniguchi, M.,
et al. (2007). Sema3a maintains normal heart rhythm through sympathetic
innervation patterning. Nat. Med. 13, 604–612. doi: 10.1038/nm1570
Janssen, B. J., Malinauskas, T., Weir, G. A., Cader, M. Z., Siebold, C., and
Jones, E. Y. (2012). Neuropilins lock secreted semaphorins onto plexins
in a ternary signaling complex. Nat. Struct. Mol. Biol. 19, 1293–1299.
doi: 10.1038/nsmb.2416
Janssen, B. J., Robinson, R. A., Pérez-Brangulí, F., Bell, C. H., Mitchell, K. J.,
Siebold, C., et al. (2010). Structural basis of semaphorin-plexin signalling.
Nature 467, 1118–1122. doi: 10.1038/nature09468
Karsenty, G., and Ferron, M. (2012). The contribution of bone to whole-organism
physiology. Nature 481, 314–320. doi: 10.1038/nature10763
Kitsukawa, T., Shimizu, M., Sanbo, M., Hirata, T., Taniguchi, M., Bekku, Y., et al.
(1997). Neuropilin-semaphorin III/D-mediated chemorepulsive signals play
a crucial role in peripheral nerve projection in mice. Neuron 19, 995–1005.
doi: 10.1016/s0896-6273(00)80392-x
Koga, T., Inui, M., Inoue, K., Kim, S., Suematsu, A., Kobayashi, E., et al.
(2004). Costimulatory signals mediated by the ITAM motif cooperate with
RANKL for bone homeostasis. Nature 428, 758–763. doi: 10.1038/nature
02444
Kolodkin, A. L., Levengood, D. V., Rowe, E. G., Tai, Y. T., Giger, R. J., and
Ginty, D. D. (1997). Neuropilin is a semaphorin III receptor. Cell 90, 753–762.
doi: 10.1016/S0092-8674(00)80535-8
Koshihara, Y., Kodama, S., Ishibashi, H., Azuma, Y., Ohta, T., and Karube, S.
(1999). Reversibility of alendronate-induced contraction in human
osteoclast-like cells formed from bone marrow cells in culture. J. Bone
Miner. Metab. 17, 98–107. doi: 10.1007/s007740050071
Kruger, R. P., Aurandt, J., and Guan, K. L. (2005). Semaphorins command cells to
move. Nat. Rev. Mol. Cell Biol. 6, 789–800. doi: 10.1038/nrm1740
Lee, C. C., Kreusch, A., McMullan, D., Ng, K., and Spraggon, G. (2003).
Crystal structure of the human neuropilin-1 b1 domain. Structure 11, 99–108.
doi: 10.1016/s0969-2126(02)00941-3
Li, Y., Yang, L., He, S., and Hu, J. (2015). The effect of semaphorin 3A on fracture
healing in osteoporotic rats. J. Orthop. Sci. 20, 1114–1121. doi: 10.1007/s00776-
015-0771-z
Luo, Y., Raible, D., and Raper, J. A. (1993). Collapsin: a protein in brain that
induces the collapse and paralysis of neuronal growth cones. Cell 75, 217–227.
doi: 10.1016/0092-8674(93)80064-l
McKenna, C. C., Ojeda, A. F., Spurlin, J., Kwiatkowski, S., and Lwigale, P. Y.
(2014). Sema3A maintains corneal avascularity during development by
inhibiting Vegf induced angioblast migration. Dev. Biol. 391, 241–250.
doi: 10.1016/j.ydbio.2014.04.017
Moretti, S., Procopio, A., Lazzarini, R., Rippo, M. R., Testa, R., Marra, M.,
et al. (2008). Semaphorin3A signaling controls Fas (CD95)-mediated apoptosis
by promoting Fas translocation into lipid rafts. Blood 111, 2290–2299.
doi: 10.1182/blood-2007-06-096529
Nakamura, F., Tanaka, M., Takahashi, T., Kalb, R. G., and Strittmatter, S. M.
(1998). Neuropilin-1 extracellular domains mediate semaphorin D/III-
induced growth cone collapse. Neuron 21, 1093–1100. doi: 10.1016/s0896-
6273(00)80626-1
Negishi-Koga, T., and Takayanagi, H. (2012). Bone cell communication
factors and semaphorins. Bonekey Rep. 1:183. doi: 10.1038/bonekey.
2012.183
Neufeld, G., and Kessler, O. (2008). The semaphorins: versatile regulators of
tumour progression and tumour angiogenesis. Nat. Rev. Cancer 8, 632–645.
doi: 10.1038/nrc2404
Frontiers in Cellular Neuroscience | www.frontiersin.org 7 February 2017 | Volume 11 | Article 40
Li et al. Semaphorin 3A Works in Skeleton
Nogi, T., Yasui, N., Mihara, E., Matsunaga, Y., Noda, M., Yamashita, N., et al.
(2010). Structural basis for semaphorin signalling through the plexin receptor.
Nature 467, 1123–1127. doi: 10.1038/nature09473
Okada, S., Nakamura, M., Katoh, H., Miyao, T., Shimazaki, T., Ishii, K., et al.
(2006). Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive
astrocytes after spinal cord injury.Nat. Med. 12, 829–834. doi: 10.1038/nm1425
Okubo, M., Kimura, T., Fujita, Y., Mochizuki, S., Niki, Y., Enomoto, H., et al.
(2011). Semaphorin 3A is expressed in human osteoarthritic cartilage and
antagonizes vascular endothelial growth factor 165-promoted chondrocyte
migration: an implication for chondrocyte cloning. Arthritis Rheum. 63,
3000–3009. doi: 10.1002/art.30482
Polleux, F., Morrow, T., and Ghosh, A. (2000). Semaphorin 3A is a
chemoattractant for cortical apical dendrites. Nature 404, 567–573.
doi: 10.1038/35007001
Rodda, S. J., and McMahon, A. P. (2006). Distinct roles for Hedgehog and
canonical Wnt signaling in specification, differentiation and maintenance of
osteoblast progenitors. Development 133, 3231–3244. doi: 10.1242/dev.02480
Sandhu, H. S., Herskovits, M. S., and Singh, I. J. (1987). Effect of surgical
sympathectomy on bone remodeling at rat incisor and molar root sockets.
Anat. Rec. 219, 32–38. doi: 10.1002/ar.1092190107
Serre, C. M., Farlay, D., Delmas, P. D., and Chenu, C. (1999). Evidence for a dense
and intimate innervation of the bone tissue, including glutamate-containing
fibers. Bone 25, 623–629. doi: 10.1016/s8756-3282(99)00215-x
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S.,
Lüthy, R., et al. (1997). Osteoprotegerin: a novel secreted protein involved
in the regulation of bone density. Cell 89, 309–319. doi: 10.1016/S0092-
8674(00)80209-3
Sims, N. A., andMartin, T. J. (2014). Coupling the activities of bone formation and
resorption: a multitude of signals within the basic multicellular unit. Bonekey
Rep. 3:481. doi: 10.1038/bonekey.2013.215
Soker, S., Takashima, S., Miao, H. Q., Neufeld, G., and Klagsbrun, M. (1998).
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-
specific receptor for vascular endothelial growth factor. Cell 92, 735–745.
doi: 10.1016/s0092-8674(00)81402-6
Takagawa, S., Nakamura, F., Kumagai, K., Nagashima, Y., Goshima, Y., and
Saito, T. (2013). Decreased semaphorin3A expression correlates with disease
activity and histological features of rheumatoid arthritis. BMC Musculoskelet.
Disord. 14:40. doi: 10.1186/1471-2474-14-40
Takahashi, T., Fournier, A., Nakamura, F., Wang, L. H., Murakami, Y.,
Kalb, R. G., et al. (1999). Plexin-neuropilin-1 complexes form functional
semaphorin-3A receptors. Cell 99, 59–69. doi: 10.1016/s0092-8674(00)
80062-8
Takahashi, T., and Strittmatter, S. M. (2001). Plexina1 autoinhibition by the
plexin sema domain. Neuron 29, 429–439. doi: 10.1016/s0896-6273(01)
00216-1
Takeda, S. (2008). Central control of bone remodelling. J. Neuroendocrinol. 20,
802–807. doi: 10.1111/j.1365-2826.2008.01732.x
Takeda, S., Elefteriou, F., Levasseur, R., Liu, X., Zhao, L., Parker, K. L., et al. (2002).
Leptin regulates bone formation via the sympathetic nervous system. Cell 111,
305–317. doi: 10.1016/s0092-8674(02)01049-8
Takegahara, N., Takamatsu, H., Toyofuku, T., Tsujimura, T., Okuno, T.,
Yukawa, K., et al. (2006). Plexin-A1 and its interaction with DAP12 in
immune responses and bone homeostasis. Nat. Cell Biol. 8, 615–622.
doi: 10.1038/ncb1416
Tamagnone, L., Artigiani, S., Chen, H., He, Z., Ming, G. I., Song, H., et al.
(1999). Plexins are a large family of receptors for transmembrane, secreted and
GPI-anchored semaphorins in vertebrates. Cell 99, 71–80. doi: 10.1016/s0092-
8674(00)80063-x
Taniguchi, M., Yuasa, S., Fujisawa, H., Naruse, I., Saga, S., Mishina, M., et al.
(1997). Disruption of semaphorin III/D gene causes severe abnormality
in peripheral nerve projection. Neuron 19, 519–530. doi: 10.1016/s0896-
6273(00)80368-2
Teitelbaum, S. L. (2000). Bone resorption by osteoclasts. Science 289, 1504–1508.
doi: 10.1126/science.289.5484.1504
Togari, A., Mogi, M., Arai, M., Yamamoto, S., and Koshihara, Y. (2000).
Expression of mRNA for axon guidance molecules, such as semaphorin-III,
netrins and neurotrophins, in human osteoblasts and osteoclasts. Brain Res.
878, 204–209. doi: 10.1016/s0006-8993(00)02700-1
Tolofari, S. K., Richardson, S. M., Freemont, A. J., and Hoyland, J. A.
(2010). Expression of semaphorin 3A and its receptors in the human
intervertebral disc: potential role in regulating neural ingrowth in the
degenerate intervertebral disc. Arthritis Res. Ther. 12:R1. doi: 10.1186/
ar2898
Toyofuku, T., Yoshida, J., Sugimoto, T., Zhang, H., Kumanogoh, A., Hori, M.,
et al. (2005). FARP2 triggers signals for Sema3A-mediated axonal repulsion.
Nat. Neurosci. 8, 1712–1719. doi: 10.1038/nn1596
Tran, T. S., Kolodkin, A. L., and Bharadwaj, R. (2007). Semaphorin
regulation of cellular morphology. Annu. Rev. Cell Dev. Biol. 23, 263–292.
doi: 10.1146/annurev.cellbio.22.010605.093554
Vadasz, Z., Haj, T., Halasz, K., Rosner, I., Slobodin, G., Attias, D., et al.
(2012). Semaphorin 3A is a marker for disease activity and a potential
immunoregulator in systemic lupus erythematosus. Arthritis Res. Ther.
14:R146. doi: 10.1186/ar3881
Wu, X., Tu, X., Joeng, K. S., Hilton, M. J., Williams, D. A., and Long, F. (2008).
Rac1 activation controls nuclear localization of β-catenin during canonicalWnt
signaling. Cell 133, 340–353. doi: 10.1016/j.cell.2008.01.052
Xie, W., Strong, J. A., Mao, J., and Zhang, J. M. (2011). Highly localized
interactions between sensory neurons and sprouting sympathetic fibers
observed in a transgenic tyrosine hydroxylase reporter mouse. Mol. Pain 7:53.
doi: 10.1186/1744-8069-7-53
Yamashita, T., Takahashi, N., and Udagawa, N. (2012). New roles of
osteoblasts involved in osteoclast differentiation. World J. Orthop. 3, 175–181.
doi: 10.5312/wjo.v3.i11.175
Zanata, S. M., Hovatta, I., Rohm, B., and Püschel, A. W. (2002). Antagonistic
effects of Rnd1 and RhoD GTPases regulate receptor activity in semaphorin
3A-induced cytoskeletal collapse. J. Neurosci. 22, 471–477.
Zhu, Y., Romero, M. I., Ghosh, P., Ye, Z., Charnay, P., Rushing, E. J., et al.
(2001). Ablation of NF1 function in neurons induces abnormal development
of cerebral cortex and reactive gliosis in the brain. Genes Dev. 15, 859–876.
doi: 10.1101/gad.862101
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Li, Hao, Duan, Wu, Zhou, Yang, Li, Zhao and Huang. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution and reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Cellular Neuroscience | www.frontiersin.org 8 February 2017 | Volume 11 | Article 40
